Kaplan-Meier analysis of overall survival in lung cancer patients based on IL-34 and CD163 expression showed that patients with high expression of both IL-34 and CD163 have the poorest survival compared to other groups (Fig. 5d). This evidence concerns the gene CD163 and lung carcinoma.